Vanda Pharmaceuticals Inc.

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:59:16 18/06/2025 BST			5-day change	1st Jan Change
4.525 ^USD	+0.78%		-2.90%	-5.53%

06-12	Vanda Pharmaceuticals Inc., Q1 2025 Earnings Call, May 07, 2025
06-10	Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2S	CI

Sector Update: Health Care

Published on 07/05/2024 at 18:35, updated on 07/05/2024 at 18:36

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc., Q1 2025 Earnings Call, May 07, 2025	06-12
Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2S	06-10	CI
Vanda Pharmaceuticals Announces First Patient Dosed In A Trial Evaluating VCA-894A In Charcot-Marie-Tooth Disease Type 2S	06-10	RE
Vanda Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-07	CI
Vanda Pharmaceuticals Inc. Reiterates Revenue Guidance for the Full Year 2025	05-07	CI
Vanda Pharmaceuticals Says FDA Accepts Bysanti Application for Bipolar I, Schizophrenia	05-05	MT
Drugmaker Vanda Announces Bysanti NDA Filing	05-05	RE
Vanda Pharmaceuticals Inc. Announces Bysanti NDA Filing	05-05	CI
Vanda Pharmaceuticals Seeks US FDA Approval for Bysanti to Treat Schizophrenia, Acute Bipolar I Disorder	03-31	MT
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti? for the Treatments of Acute Bipolar I Disorder and Schizophrenia	03-31	CI
Vanda Raises Concerns Over FDA Review Timeline for Motion Sickness Therapy Candidate	03-17	MT
Vanda Pharmaceuticals Inc. Announces the Publication of an Article Article Entitled "Potential ASO-Based Personalized Treatment for Charcot-Marie-Tooth Disease Type 2S	02-24	CI
Vanda Pharmaceuticals Inc., Q4 2024 Earnings Call, Feb 13, 2025	02-13
Vanda Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	02-13	CI
Vanda Pharmaceuticals Inc. Provides Revenue Guidance for the Year 2025 and 2030	02-13	CI
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab	02-03	CI
Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab	02-03	MT
Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab	02-03	RE
US retail investors dive into tech stocks in response to DeepSeek selloff	01-30	RE
Vanda Pharmaceuticals Inc. Accepts FDA Opportunity for A Hearing on New Drug Application for Tradipitant in Gastroparesis	01-27	CI
Vanda Pharmaceuticals Highlights Issues in Gastroparesis Treatment Application Review in Letter to FDA Commissioner	01-08	MT
Vanda Pharmaceuticals' Prospective Treatment for Blood Cancer Receives US FDA's Orphan Drug Designation	12-20	MT
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q3 Revenue $47.7M	11-06	MT
Vanda Pharmaceuticals Inc., Q3 2024 Earnings Call, Nov 06, 2024	11-06
Vanda Pharmaceuticals Inc. Revises Revenue Guidance for the Full Year 2024	11-06	CI

Chart Vanda Pharmaceuticals Inc.

Duration

Period

VNDA: Dynamic Chart

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâs commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Employees

368

Sector

Biotechnology & Medical Research

Calendar

07-23 - Q2 2025 Earnings Release (Projected)

More about the company